Cancer treatment outcomes often depend on an overlooked biomarker — albumin.
During cancer treatment, many patients may receive the same therapy yet experience markedly different responses and levels of tolerance.
Research suggests that these differences are not solely related to the tumor itself, but are also closely linked to the patient’s overall physiological condition. One key indicator is albumin (Human Serum Albumin, HSA).
Multiple studies have shown that low albumin levels are significantly associated with higher rates of treatment interruption, increased risk of complications, and poorer overall prognosis in cancer patients (McMillan, 2001; Gupta & Lis, 2010).









